Clinical Trial

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
Protocol Amendment History 1 change
notable Trial sites expanded: 14 -> 22 locations 2026-04-01
Trial Details
NCT Number NCT05957367
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions GIST
Enrollment 94 participants
Start Date 2023-09-28
Primary Completion 2027-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-23